Opus Genetics (IRD) Revenue (2010 - 2026)

Opus Genetics (IRD) has 8 years of Revenue data on file, last reported at $2.2 million in Q1 2026.

• Revenue for Q1 2026 came in at $2.2 million, down 50.64% year-over-year; the trailing twelve-month figure through Mar 2026 was $12.0 million (down 12.22% YoY), and the FY2025 annual result was $14.2 million, up 29.15% from the prior year.
• Revenue fell to $2.2 million in Q1 2026 per IRD's latest filing, from $3.9 million in the prior quarter.
• Over five years, Revenue peaked at $39.8 million in Q4 2022 and troughed at $1.1 million in Q2 2024.
• A 5-year average of $6.2 million and a median of $3.4 million in 2023 frame the typical range for Revenue.
• The sharpest annual moves came in 2023 and 2025: Revenue sank 95.76% in 2023, then soared 159.17% in 2025.
• A 5-year view of Revenue shows it stood at $39.8 million in 2022, then slumped by 95.76% to $1.7 million in 2023, then surged by 154.41% to $4.3 million in 2024, then fell by 10.16% to $3.9 million in 2025, then tumbled by 44.19% to $2.2 million in 2026.
• Business Quant data shows IRD's Revenue at $2.2 million in Q1 2026, $3.9 million in Q4 2025, and $3.1 million in Q3 2025.